Certolizumab Pegol
Brand Names: Cimzia
Methodology & AI Transparency ⓘ
Certolizumab Pegol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage cimzia: is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 77% satisfaction benchmark (RxCUI 795081).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Certolizumab Pegol tolerability events: cutaneous rash (3.9%), nasopharyngitis (8.7%), nausea (7.4%).
Ask our AI Specialists anything about Certolizumab Pegol
Certolizumab Pegol Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage cimzia: is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis.
12.1 Mechanism of Action Certolizumab pegol binds to human TNFα with a KD of 90pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol selectively neutralizes TNFα (IC 90 of 4 ng/mL for inhibition of human TNFα in the in vitro L929 murine fibrosarcoma cytotoxicity assay) but does not neutralize lymphotoxin α (TNFβ). Certolizumab pegol cross-reacts poorly with TNF from rodents and rabbits, therefore in vivo efficacy was evaluated using animal models in which human TNFα was the physiologically active molecule.
Pharmacokinetic profiling of Certolizumab Pegol demonstrates an elimination half-life of Approximately 6–13 hours terminal plasma half-life for Certolizumab Pegol with Complete (~100%) parenteral systemic delivery for Certolizumab Pegol (200 mg/mL Injection, Solution) systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of certolizumab pegol coupled with glomerular and tubular renal excretion, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after certolizumab pegol administration.
Titration schedules for Certolizumab Pegol (200 mg/mL Injection, Solution → Kit) require excluding 4 contraindications cimzia is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients.; reactions have included angioedema, anaphylaxis, serum sickness, and urticaria .; serious hypersensitivity reaction to certolizumab pegol or to any of the excipients.; real-world patient logs highlight nasopharyngitis (8.7% of reports), headache (7.6% of reports), nausea (7.4% of reports) alongside a 77.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Certolizumab Pegol (tumor necrosis factor blocker).
Unstandardized herbal extracts may interact pharmacodynamically with Certolizumab Pegol maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients.
- Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria .
- Serious hypersensitivity reaction to certolizumab pegol or to any of the excipients.
Logged Side-Effect Incidence (21 Reports)
Certolizumab Pegol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Certolizumab Pegol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data CZP plasma concentrations were influenced by both dose and dose adjustment in a predictable manner, with median plasma levels twice as high in the 400-mg group than in the 200-mg group, with a 2-fold increase after the dose... Therapeutic drug monitoring • 2026-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41622540 ↗ |
| Can This Approach Help? Inside the Latest Research on Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion Early and sustained suppression of inflammation mitigates the risk of long-term FL development in the spine in study participants with axSpA evaluated over 4 years. Rheumatology (Oxford, England) • 2022-07-06 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34791107 ↗ |
| Can This Approach Help? Inside the Latest Research on Three-year real-world benefits and safety of certolizumab pegol for the treatment Response to CZP was durable over three years; no new safety signals were identified. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34192387 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis Both CZP 200 mg and 400 mg Q2W demonstrated sustained, durable efficacy, with numerically higher responses for some outcomes with 400 mg Q2W. The British journal of dermatology • 2021-04-15 • Phase III Randomized Trial | N = 186 | 88/100 | PMID 32652544 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploratory analysis of the potential disconnect between objective inflammatory There is a potential disconnect between objective measures of inflammation and clinical outcome responses in patients with axSpA. RMD open • 2024-08-28 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39209369 ↗ |
Certolizumab Pegol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5783.3464/unit (~$173500.39/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Certolizumab Pegol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Certolizumab Pegol RxNorm Concept ID | 795081 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5783.3464 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Certolizumab Pegol Patient Community, Cohort Filters & Dosage Logs
Cross-verified Certolizumab Pegol (tumor necrosis factor blocker) monograph synthesizing RxNorm 795081, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Certolizumab Pegol community threads and patient logs by age, biological sex, dosage, and treatment duration.